Ibrance/Palbocyclib - experience for locally advanced BC?

[sashbash]

Hi all

I keep reading about Ibrance and Palbocyclib and their successful impact on met BC.

I hoped I'd get in as part of a trial (I'm ER +, Her2-, stage 3) but have just found out that I wasn't selected. I am gutted.

It's not available on the NHS yet in the UK for primary BC, but I'd be really interested to hear from any women who've been prescribed it elsewhere...

Sash

[carolinenailsea]

Sashbash

Sorry I cannot help in that I have not heard of the drugs you mention or the trial. I am sad you did not get your wish to be included in the trial. I wish you all the best. Caroline xx

[Choey]

Hi sashbash, carolinenailsea and all,

I was also a candit to the Pallas trial but I was randomise on the Standard adjuvant endocrine therapy.

I also keep reading about Ibrance and Palbocyclib and their successful impact on met BC.

I am not from the UK.

I looked at the indication for IBRANCE (Palbociclib) in "EMA" and in "NICE" "Technology appraisal guidance" and as far as I understand it is indicated for locally advance breast cancer in the 20th of December 2017. (Please look at the attached quotes and links below)

I didn’t find a the definition of locally advanced in the indication for IBRANCE in NICE or EMA.

1. Were you successful in getting the medicine in the end?

2. Do you know what is the definition of locally advanced in the indication for IBRANCE in NICE or EMA?

3. Are you aware of specific countries in the world(for example England) or other recommendation that will indicate IBRANCE for locally advanced breast cancer that is amenable to resection or radiation therapy with curative intent?

The "Marketing authorisation" from NICE website:

Palbociclib is indicated for treating 'hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative "locally advanced" or metastatic breast cancer:

in combination with an aromatase inhibitor“

Links:

nice.org.uk/guidance/ta495/...

The "Therapeutic indications" from EMA:

"Therapeutic indications

IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative "locally advanced" or metastatic breast cancer:

• - in combination with an aromatase inhibitor;”

Links:

ema.europa.eu/ema/index.jsp...

ema.europa.eu/docs/en_GB/do...

Thanks,

Choey.